Thelansis

Acute Radiation Syndrome (ARS) Market Outlook Thelansis’s “Acute Radiation Syndrome (ARS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Radiation Syndrome (ARS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact o...

Acute Radiation Syndrome (ARS) Market Outlook Thelansis’s “Acute Radiation Syndrome (ARS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Radiation Syndrome (ARS)       treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Acute Radiation Syndrome (ARS) Overview Acute radiation syndrome (ARS) is a set of conditions that occur in humans following brief exposure to ionizing radiation at doses exceeding 0.7–1.0 Gy. The stages of ARS are as follows: Prodromal Phase: Begins within hours of exposure and can last up to 2 days. Latent Phase: A transitional period during which the patient shows no symptoms, las...

 Acute radiation syndrome (ARS) is a set of conditions that occur in humans following brief exposure to ionizing radiation at doses exceeding 0.7–1.0 Gy. The stages of ARS are as follows: 1.        Prodromal Phase: Begins within hours of exposure and can last up to 2 days. 2.        Latent Phase: A transitional period during which the patient shows no symptoms, lasting up to three weeks but shorter with higher radiation doses. 3.        Illness Phase: Characterized by clinical symptoms such as infection, bleeding, diarrhea, electrolyte imbalances, altered mental state, and shock. 4.        Death or Recovery Phase: Typically unfolds over weeks or months. There are specific forms of ARS, depending on radiation exposure: ·        Bone marrow syndrome (0.7 to 10.0 Gy) ·        Gastrointestinal s...

 Acute radiation syndrome (ARS) is a complex of syndromes developed in humans due to short-duration whole-body exposure to ionizing radiation with doses higher than 0.7–1.0 Gy. The prodromal phase occurs within hours of exposure and may last up to 2 days. The latent phase is a transitional period in which the patient is asymptomatic. This may last as long as three weeks but is much shorter with higher radiation exposures. The illness phase produces overt clinical manifestations, including infection because of leukopenia, bleeding from thrombocytopenia, diarrhea, electrolyte imbalances, altered mental status, and shock. The death or recovery phase often occurs over weeks or months. Bone marrow syndrome (dose from 0.7 to 10.0 Gy), gastrointestinal syndrome (above 8.0 Gy), cardiovascular syndrome (above 20.0 Gy), central nervous system (or neurological) syndrome (above 80.0 Gy), and cutaneous (skin) syndrome (above 10.0 Gy) ·        As per Thelansis’ re...